Menu

“Ghost Fibers” Help Heal Muscle Injury

Injured muscle cells leave behind organized collagen fibers that act as scaffolding for new tissue growth.

Dec 15, 2015
Karen Zusi

Activated muscle stem/progenitor cells (white) moving within basal lamina remnants (ghost fibers in red)CARNEGIE INSTITUTE FOR SCIENCE: MICAH WEBSTER, CHEN-MING FAN; NICHD: JENNIFER LIPPINCOTT-SCHWARTZ, URI MANORAt the site of a muscle injury, the dying muscle fibers leave behind “ghost fibers,” remnants of the extracellular matrix. According to a study published by researchers from the Carnegie Institution for Science and the National Institute of Child Health and Human Development last week (December 10) in Cell Stem Cell, these fibers help guide new muscle cells to grow in place to heal the injury in mice.

The research team anesthetized a set of mice and then either injected the animals’ hind limb muscles with a cardiotoxin or made manual incisions into the muscle. The striated muscle tissue began disappearing from wound sites one day after injury, leaving behind a series of collagen ghost fibers.

Using two-photon imaging and second-harmonic generation microscopy, the team was able to observe the stem cells and muscle precursor cells in each mouse orienting themselves along the ghost fibers as they prepared to grow new muscle tissue. When the researchers perturbed the system and changed the orientation of the ghost fibers, the resulting muscle tissue grew back improperly.

In their paper, the authors proposed that “the ghost fiber (1) is a key determinant for patterning muscle stem cell behavior and (2) provides the foundation for proportional regeneration.”

“We conclude that ghost fibers are autonomous, architectural units necessary for proportional regeneration after tissue injury,” the authors wrote. “This finding reinforces the need to fabricate bioengineered matrices that mimic living tissue matrices for tissue regeneration therapy.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.